Transaction Advisory Services
About Transaction Advisory Services
EY TAS is dedicated to assist our clients to achieve their long-term competition by driving capital allocation and transaction strategy through execution to enable fast-track value creation. We support the flow of capital across borders, help bring new products and innovation to market and enable organizations to reshape themselves for a better future.
With global scale and connectivity, we enable our clients to navigate complexity and build a better working world by fostering inclusive growth, prosperity and social value.
With more than 20 years of transaction advisory experiences in Greater China, our team provides comprehensive and high value-added services to support our clients throughout the M&A process. Our dedicated transaction advisory services cover growth and M&A strategy, transaction execution, post-deal integration and divestment. We also provide restructuring and business turnaround services to debtors, creditors and other stakeholders.
We help our clients enhance their business value and improve returns to key stakeholders including shareholders and employees through the formulation of forward-looking growth strategies, advice on transaction execution, management of the transaction integration process, and development of post-transaction assessments and monitoring mechanisms.
As the global economy becomes more connected and integrated, and our clients become more globalized, our team of 9,400 transaction advisory professionals from over 90 countries is equipped to deliver integrated transaction advisory services to support our clients’ global growth and development ambitions.
In response to our clients’ needs for international experience, global market insights, and a deep understanding of the local market during the M&A process, our team of more than
800 dedicated Transaction Advisory Services professionals in Greater China is committed to working seamlessly with our global team to provide timely and insightful advice.
Following the two-invoice policy roll-out for pharma, one can expect this will pose similar impacts on MedTech stakeholders.